Stock Analysis

Novolog (Pharm-Up 1966) First Quarter 2024 Earnings: EPS: ₪0.024 (vs ₪0.02 loss in 1Q 2023)

Source: Shutterstock

Novolog (Pharm-Up 1966) (TLV:NVLG) First Quarter 2024 Results

Key Financial Results

  • Revenue: ₪438.0m (up 6.0% from 1Q 2023).
  • Net income: ₪12.0m (up from ₪10.0m loss in 1Q 2023).
  • Profit margin: 2.7% (up from net loss in 1Q 2023).
  • EPS: ₪0.024 (up from ₪0.02 loss in 1Q 2023).
TASE:NVLG Earnings and Revenue History May 22nd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Novolog (Pharm-Up 1966) shares are down 1.7% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Novolog (Pharm-Up 1966) that you need to take into consideration.

Valuation is complex, but we're helping make it simple.

Find out whether Novolog (Pharm-Up 1966) is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.